优化布科粘合剂repaglinide装载的cubogel:在线体表征和体内低血糖活性在链毒素诱导的糖尿病大鼠模型中
Nihal Farid Younes1, Randa Latif1, Alia Badawi1
1Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini Street, Cairo 11562, Egypt.
International journal of pharmaceutics: X
|July 29, 2025
概括
装有Repaglinide的cubogels被开发为一种粘系统,以改善II型糖尿病的管理. 这种新型药物输送系统在糖尿病大鼠中显示出增强的粘膜粘合,延长药物释放,并显著降低血糖.
科学领域:
- 制药科学 制药科学
- 药物输送系统 药物输送系统
- 纳米技术纳米技术
背景情况:
- 口服Repaglinide的生物利用性有限,这对糖尿病管理构成了挑战.
- 嘴粘合剂药物输送系统提供了一个潜在的解决方案,以提高治疗疗效.
研究的目的:
- 开发和优化repaglinide装载的立方体和立方体凝,用于布卡粘合剂的输送.
- 为了评估优化的cubogel配方的体外和体外性能.
主要方法:
- 使用Box-Behnken设计准备和优化了Repaglinide立方体.
- 通过将凝剂 (HPMC/CMC) 纳入优化的立方体体中,使用因数设计来制备Cubogels.
- 描述包括溶解效率,颗粒大小,泽塔潜力,粘膜粘合,药物释放,风湿学,活体透和活体药理学.
主要成果:
- 优化立方体 (Opt-RPG-CUB) 显示出高溶解效率 (88.01%),最佳粒子大小 (252.55 nm) 和负泽塔电位 (-31.13 mV).
- 优化的cubogel (Opt-RPG-Cubogel) 呈现出强烈的粘膜粘合 (>9小时),持续24小时的药物释放,以及增强的粘膜透.
- 在糖尿病大鼠的体内实验证实了显著的血糖降低,孔焦显微镜显示深层粘膜透.
结论:
- 装有Repaglinide的立方体凝是一种有前途的粘性药物输送系统.
- 这种配方增强了药物的生物可用性,并为II型糖尿病管理提供了有效的策略.
相关概念视频
01:06Oral Hypoglycemic Agents: Glinides
263
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
263
01:24Glucagon-like Receptor Agonists
420
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
420
01:23Dipeptidyl Peptidase 4 Inhibitors
261
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
261
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
304
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
304
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
263
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
263